Alkem Labs Subsidiary Enzene Biosciences Secures ₹26.16 Crore Funding
Alkem Laboratories' subsidiary, Enzene Biosciences, has entered into an agreement for a preferential allotment of securities. F-Prime Capital and ERVI Healthcare will invest ₹26.16 crore in Enzene for Series B CCPS and equity shares. This amendment also covers adherence to the Shareholders' Agreement and modifies certain provisions.
The funding is for a subsidiary and represents a minority stake acquisition, thus having a moderate impact on the parent company, Alkem Laboratories. The amount raised is significant for the subsidiary but not transformative for Alkem's overall scale.
The announcement details a significant funding round for the subsidiary, Enzene Biosciences, which is expected to strengthen its financial position and support its growth initiatives. The infusion of capital from new investors is a positive development.
Alkem Laboratories Limited announced an Amendment cum Supplemental Agreement dated 13th February 2026 concerning its subsidiary, Enzene Biosciences Limited. This agreement involves Eight Roads Ventures India Healthcare IV, L.P. ("Eight Roads Ventures"), F-Prime Capital Partners Life Sciences Fund VI LP ("F-Prime Capital"), and ERVI Healthcare IV Holdings Limited ("ERVI Healthcare").
The primary purpose of this amendment is to facilitate the allotment of securities by Enzene to F-Prime Capital and ERVI Healthcare on a preferential basis through a private placement. Additionally, ERVI Healthcare will adhere to the terms of the existing Shareholders' Agreement, and certain provisions of the agreement have been amended.
F-Prime Capital and ERVI Healthcare will collectively infuse an aggregate amount of ₹26,16,25,003 for the subscription of 5,58,302 Series B Compulsorily Convertible Preference Shares (CCPS) and 10 Equity Shares of Enzene. Specifically, F-Prime will subscribe to 1,30,451 Series B CCPS, and ERVI Healthcare will subscribe to 4,27,851 Series B CCPS and 10 Equity Shares. The issue price for each Series B CCPS and Equity Share is ₹468.60, including a premium of ₹458.60 per share.
Following this transaction, Alkem Laboratories will hold 88.99% of Enzene's total share capital on a fully diluted basis. Eight Roads Ventures will hold 5.42%, F-Prime Capital 1.87%, and ERVI Healthcare 0.71%. The company confirmed that this transaction does not fall within the purview of related party transactions.
What to do with a filing like this
Alkem Laboratories Limited filed this with the NSE as a statutory disclosure, categorised under other corporate actions. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Alkem Laboratories Limited. Read the original for the full detail.